Hepatic metastasis of mucinous adenocarcinoma with neuroendocrine differentiation harboring a rare HER2 R678Q mutation: a case report and literature review - Scorecard - MDSpire
Advertisement
Hepatic metastasis of mucinous adenocarcinoma with neuroendocrine differentiation harboring a rare HER2 R678Q mutation: a case report and literature review
Clinical Scorecard: Hepatic Metastasis of Mucinous Adenocarcinoma with Neuroendocrine Features and a Unique HER2 R678Q Mutation: A Case Study and Review of Existing Literature
At a Glance
Category
Detail
Condition
Key Mechanisms
HER2 (ERBB2) R678Q mutation and neuroendocrine differentiation (source needed).
Target Population
Care Setting
Key Highlights
First reported case of MAC with neuroendocrine features harboring a HER2 R678Q mutation (source needed).
Patient received FOLFOX chemotherapy and trastuzumab based on HER2 status (source needed).
Tumor showed early resistance to treatment and continued progression (source needed).
Emphasizes the need for broad molecular testing in CUP diagnosis (source needed).
Highlights limited efficacy of HER2-targeted therapies in rare mutations (source needed).
Guideline-Based Recommendations
Diagnosis
Comprehensive diagnostic evaluation for CUP is essential (source needed).
Management
Consider broad molecular profiling to identify actionable mutations (source needed).
Monitoring & Follow-up
Monitor tumor markers and disease progression closely (source needed).
Risks
High risk of disease progression despite treatment in rare mutations (source needed).
Patient & Prescribing Data
50-year-old male with CUP and multiple metastases.
FOLFOX chemotherapy with trastuzumab was initiated based on HER2 mutation.
Clinical Best Practices
Integrate genomic testing into the diagnostic process for CUP (source needed).
Tailor treatment strategies based on identified molecular alterations (source needed).
